08 October 2025 | News
Image Courtesy: Public Domain
Remedy Robotics, Inc., a leading medical technology company, debuted the world's first remotely operable endovascular robotic system. By combining proprietary hardware with AI-enabled software, the Remedy N1 System empowers clinicians to deliver faster, safer, and more effective intervention to patients with cardiovascular conditions such as stroke, heart attack, or vascular trauma – whether they are across the room or across the globe. This groundbreaking technology will both elevate the standard of cardiovascular care and dramatically expand access to treatment for time-critical conditions.
The Remedy N1 System recently completed a series of first-ever, in-human procedures led by Vitor Mendes Pereira, MD, a world-renowned neurosurgeon at St. Michael's Hospital, Toronto. These procedures included fully remote operations conducted between two separate hospitals within the Unity Health Toronto network: St. Michael's Hospital and St. Joseph's Health Centre. Marking the world's first entirely remotely operated endovascular interventions, these procedures demonstrate the potential of the Remedy N1 System to deliver life-saving treatments for cardiovascular emergencies such as stroke, regardless of distance.
"By successfully completing these first remote procedures in humans, we're not just introducing a breakthrough technology - we're taking real steps towards ensuring that every person around the world has access to the best possible endovascular care," said Dr. David Bell, CEO and Co-Founder of Remedy Robotics. "This milestone is a testament to our team's dedication and hard work with our clinical partners, like Dr. Pereira and Unity Health Toronto. We're building a solution that will transform cardiovascular care globally and we're grateful to be able to work with the world's best clinicians to get it out there."
Cardiovascular diseases, such as stroke and heart attack, are the leading cause of death and disability worldwide, responsible for more than 19 million deaths each year, according to the National Institutes of Health. Stroke alone carries an immense economic burden, with the World Stroke Organization estimating annual global costs of nearly $900 billion. While endovascular intervention is considered the gold standard of care, it is only currently available at select specialist hospitals. As a result, only 2.8% of eligible stroke patients worldwide have access, underscoring a critical gap in life-saving treatment.
Jake Sganga, PhD , CTO and Co-Founder of Remedy Robotics, commented, "The Remedy N1 System represents the next generation of surgical robotics, using advanced AI and machine learning to enable clinicians to operate robotically with a degree of visibility, precision, and control that has never before been possible. The system is engineered for scalability, allowing for straightforward deployment at virtually any hospital and, for the first time, allowing clinicians to complete entire endovascular procedures remotely from start to finish. The N1 System will allow every hospital to provide safe and precise endovascular intervention for cardiovascular procedures, and will empower physicians to provide expert care wherever it's needed."
The Remedy N1 System includes an endovascular robot that integrates seamlessly into any catheterization laboratory. With proprietary AI-supported software, the N1 System can precisely control up to 4 tools at a time, including off the shelf wires, microcatheters, stents and coils as well as multiple sizes of proprietary 360-degree steerable catheters. Clinicians use a simple, portable console, designed for ease of deployment from both within and outside hospital environments, to perform the entire procedure robotically, including control of all tools, fluidics and audiovisual communication. The N1 System also provides integrated connectivity management as well as automated preprocessing of CT and MRI scans to allow for seamless integration, in real time, with fluoroscopic x-ray imaging.
Dr. Pereira added, "Performing minimally invasive remote robotic interventions is transformative and will open a new avenue to expand care in our field. The Remedy N1 System delivers precise maneuverability that allows for enhanced control and an overall safe procedural experience. The success of these world-first in-human remote procedures is a strong validation of the platform's precision, safety, and potential to transform patient care globally."
On speaking about its investment in Remedy Robotics, Blackbird Ventures General Partner Michael Tolo said, "Remedy Robotics is pushing the boundaries of what's possible in modern medicine. The team's ability to combine cutting-edge robotics, advanced machine learning, and real-time imaging to enable remote cardiovascular intervention is nothing short of transformative. We're proud to support a company that's not only pioneering a new era of care, but doing so with global scale and impact in mind."
"By integrating advanced AI, machine learning, and computer vision with cutting-edge hardware, Remedy Robotics is distinguishing itself from the MedTech field and leading a new generation of surgical robotics," said DCVC General Partner James Hardiman, commenting on the firm's investment in Remedy Robotics. "With this milestone, the Remedy team is poised to make a profound impact on both patient outcomes and health system operations, and we are proud to support them in their mission."
The successful completion of these first-in-human procedures marks a significant milestone for Remedy Robotics, with the company now focused on expanded clinical trials and the development of additional applications across a range of cardiovascular surgical specialties. The Remedy N1 System remains under development and is not yet available for sale.
